Source: Υπουργείο Υγείας (CY) Revision Year: 2014 Publisher: MEDOCHEMIE LTD, 1-10 Constantinoupoleos street, 3011 Limassol, Cyprus
Due to the variety of conditions, the recommended dosage regimes are variable. Irrespective of the final dosage, gradual introduction of bromocriptine to achieve the optimum response with minimal side effects is recommended. Initial dose should be given at bedtime, with dosage increments of 1.25 mg to 2.5 mg at two to three day intervals, and divided doses, until 2.5 mg twice a day is reached. Subsequent dosage increments, if needed, should be done in the same way.
The maximum daily dose is restricted to 30mg/day.
Prevention of lactation: 2.5 mg on day of delivery, followed by 2.5 mg twice a day for fourteen days. Gradual introduction is unnecessary for this indication.
Suppression of lactation: 2.5 mg on first day, increased after two or three days to 2.5 mg twice a day for fourteen days. Gradual introduction is unnecessary for this indication.
Hypogonadism/galactorrhoea/infertility: Introduce bromocriptine gradually as recommended initially. The majority of patients with hyperprolactinaemia respond to 7.5 mg daily in divided doses, but 30 mg daily has been used. Infertile patients without elevated serum prolactin usually respond to 2.5 mg twice a day.
Prolactinomas: Introduce bromocriptine gradually as recommended initially. Dosage may then be increased by 2.5 mg daily at two to three day intervals: 2.5 mg every eight hours, 2.5 mg every six hours, 5 mg every six hours. Up to 30 mg daily has been used.
Acromegaly: Standard gradual introduction, followed by dosage increments of 2.5 mg daily every two to three days to reach: 2.5 mg every eight hours, 2.5 mg every six hours, 5 mg every six hours.
Parkinson’s disease: Introduce as in the table:
| Week 1 | 1-1.25 mg at bed time. |
| Week 2 | 2-2.5 mg at bed time. |
| Week 3 | 2.5 mg two times a day. |
| Week 4 | 2.5 mg three times a day. |
| Thereafter | Three times a day, increasing by 2.5 mg every three to fourteen days, depending upon response. Continue until optimum dose achieved, usually between 10 mg and 30 mg daily. Patients concomitantly on levodopa can have the dosage reduced as bromocriptine is increased until optimum balance is achieved. |
Not appropriate for children under seven years of age.
No special dosage recommendations.
Dosage adjustment should not be necessary.
As bromocriptine is extensively metabolised in the liver, dosage reduction must be anticipated in hepatic impairment. Caution is advised.
Medocriptine tablets are for oral administration. They should be taken with a meal.
Overdosage with Medocriptine is likely to result in vomiting and other symptoms which could be due to over stimulation of dopaminergic receptors and might include nausea, dizziness, hypotension, postural hypotension, tachycardia, drowsiness, somnolence, lethargy, confusion and hallucinations. General supportive measures should be undertaken to remove any unabsorbed material and maintain blood pressure if necessary.
In the case of overdose, administration of activated charcoal is recommended and in the case of very recent oral intake, gastric lavage may be considered.
5 years.
Store below 25°C, in the original package.
Polyvinylchloride and aluminium combination blisters. Blisters and leaflet in an outer carton.
Medocriptine 2.5 mg tablets are available in packs of 30, 100 or 500 tablets.
Not all pack sizes may be marketed.
No special requirements for disposal.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
